Amplify Weight Loss Drug & Treatment ETF (THNR) Holdings
THNR holdings summary
as of Oct 25, 2026- Holdings
- 21 positions listed
- Top 10 weight
- 65.9% of net assets
- Effective holdings
- 17 equal-weight equivalent
- Largest holding
- LLY 11.57% Eli Lilly and Company
- Annual turnover
- — of the portfolio traded
All THNR holdings
| # | Name | ||||||
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly and Company | Healthcare | 11.57% | $663,730.41 | $1.12T | 42.2 |
| 2 | NVO | Novo Nordisk A/S | Healthcare | 8.57% | $491,875.54 | $171.36B | 9.1 |
| 3 | AMGN | Amgen Inc. | Healthcare | 6.30% | $361,792.18 | $233.82B | 26.9 |
| 4 | ROP | Roche Holding AG | Healthcare | 5.99% | $343,893.38 | — | — |
| 5 | ABBV | AbbVie Inc. | Healthcare | 5.95% | $341,391.34 | $504.37B | 80.6 |
| 6 | AZN | AstraZeneca PLC | Healthcare | 5.71% | $327,687.48 | — | — |
| 7 | PFE | Pfizer Inc. | Healthcare | 5.61% | $321,851.29 | $168.60B | 38.9 |
| 8 | REGN | Regeneron Pharmaceuticals, Inc. | Healthcare | 5.54% | $317,633.39 | $81.41B | 19.6 |
| 9 | 4519 | Chugai Pharmaceutical Co. Ltd. | Healthcare | 5.37% | $308,399.93 | — | — |
| 10 | GILD | Gilead Sciences, Inc. | Healthcare | 5.31% | $304,933.79 | $193.67B | — |
| 11 | MRK | Merck & Co., Inc. | Healthcare | 5.18% | $297,462.09 | $360.08B | 115.8 |
| 12 | 1093 | CSPC Pharmaceutical Group Ltd | Healthcare | 4.81% | $276,303.75 | — | — |
| 13 | 1801 | Innovent Biologics Inc | Healthcare | 4.29% | $246,015.24 | — | — |
| 14 | VKTX | Viking Therapeutics, Inc. | Healthcare | 4.04% | $232,024.45 | $3.20B | — |
| 15 | ARWR | Arrowhead Pharmaceuticals, Inc. | Healthcare | 3.56% | $204,283.89 | $7.90B | — |
| 16 | ZEAL | Zealand Pharma A/S | Healthcare | 3.51% | $201,173.55 | — | — |
| 17 | 128940 | Hanmi Pharm Co Ltd | Healthcare | 2.75% | $157,927.21 | — | — |
| 18 | GPCR | Structure Therapeutics Inc. | Healthcare | 2.36% | $135,609.66 | $1.50B | — |
| 19 | 0BO | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | Healthcare | 2.35% | $134,628.35 | — | — |
| 20 | KLRA | Kailera Therapeutics, Inc. | Healthcare | 1.12% | $64,485.03 | $1.46B | — |
| 21 | AGPXX | Invesco Short-Term Investments Trust Government & Agency Portfolio Institutional | Other | 0.24% | $13,876.02 | — | — |
Weights as a percentage of net assets. Value held = weight × net assets ($5.7M). Market cap and P/E from each company's latest fundamentals (U.S.-listed stocks).
THNR sector breakdown
Sum of the weights of the holdings in each sector.
THNR top industries
THNR overlap with other ETFs
| ETF | Fund | Overlap | Shared holdings | Expense ratio |
|---|---|---|---|---|
| PBPH | Portfolio Building Block World Pharma and… | 46.2% | 10 of 52 | — |
| PJP | Invesco Dynamic Pharmaceuticals ETF | 36.1% | 8 of 28 | 0.57% |
| DIA | SPDR Dow Jones Industrial Average ETF | 6.9% | 2 of 30 | 0.16% |
| SPY | SPDR S&P 500 ETF | 3.8% | 8 of 502 | 0.09% |
| VTI | Vanguard Total Stock Market ETF | 3.4% | 11 of 2,941 | 0.03% |
| QQQ | Invesco QQQ ETF | 2.5% | 4 of 101 | 0.17% |
Overlap = sum over shared holdings of the smaller of the two weights. 100% means identical portfolios.
About the THNR portfolio
Amplify Weight Loss Drug & Treatment ETF holds 21 positions. The ten largest make up 65.9% of the fund, so it behaves like a portfolio of about 17 equally weighted stocks. The biggest positions are Eli Lilly and Company (11.57%), Novo Nordisk A/S (8.57%), Amgen Inc. (6.30%), Roche Holding AG (5.99%), AbbVie Inc. (5.95%).
By sector, Healthcare is 99.9%, Other is 0.2%. Holdings data is from the fund's latest portfolio as reported by EODHD on October 25, 2026; positions change as the fund rebalances.
Related: THNR chart, THNR performance, THNR dividends, THNR overview.
THNR holdings FAQ
How many holdings does THNR have?
THNR holds 21 positions as of October 25, 2026.
What are the top 10 holdings of THNR?
The ten largest holdings are Eli Lilly and Company (11.57%), Novo Nordisk A/S (8.57%), Amgen Inc. (6.30%), Roche Holding AG (5.99%), AbbVie Inc. (5.95%), AstraZeneca PLC (5.71%), Pfizer Inc. (5.61%), Regeneron Pharmaceuticals, Inc. (5.54%), Chugai Pharmaceutical Co. Ltd. (5.37%), Gilead Sciences, Inc. (5.31%). Together they are 65.9% of the fund.
What percentage of THNR is Eli Lilly and Company?
Eli Lilly and Company is the largest holding at 11.57% of net assets, about $663,730.41 of the fund's $5.7M.
How concentrated is THNR?
The top 10 holdings are 65.9% of the fund. By the effective number of holdings (1 divided by the sum of squared weights) THNR behaves like a portfolio of about 17 equally weighted stocks.